Cadrenal Therapeutics announced that its first‑in‑class 12‑lipoxygenase inhibitor, CAD‑1005, has moved to a Phase 3 pivotal trial following an End‑of‑Phase‑2 meeting with the FDA on March 26, 2026. The meeting clarified the regulatory pathway and the design of the upcoming trial for patients with heparin‑induced thrombocytopenia (HIT).
In Phase 2, CAD‑1005 reduced thrombotic events when added to standard anticoagulant therapy. The FDA’s feedback will shape the primary endpoints, enrollment criteria, and safety monitoring plan for the Phase 3 study. Cadrenal will finalize the protocol and submit an Investigational New Drug application in the coming weeks.
HIT is a life‑threatening immune‑mediated disorder with mortality rates that can exceed 20 %. Current treatments rely on discontinuing heparin and switching to alternative anticoagulants, but no targeted therapy exists. CAD‑1005’s 12‑LOX inhibition offers a novel mechanism that could become the first disease‑specific treatment for HIT, opening a sizable orphan‑drug market.
Cadrenal’s financial position underscores the urgency of advancing the program. As of December 31, 2025, the company held $4.0 million in cash and cash equivalents and reported a net loss of $3.0 million in Q4 2025, an improvement from $4.2 million in Q4 2024. The full‑year 2025 net loss rose to $13.2 million from $10.7 million in 2024, reflecting continued investment in clinical development. The company is actively evaluating financing and strategic alternatives to support the Phase 3 program.
CEO Quang X. Pham emphasized the unmet need in HIT and the potential of CAD‑1005: “CAD‑1005 continues to reinforce our conviction that selective 12‑LOX inhibition may offer a differentiated approach for patients with HIT, a life‑threatening, immune‑mediated prothrombotic disorder, and a serious condition with substantial unmet need.” He added that the EOP2 meeting was an important milestone and that Cadrenal remains focused on advancing CAD‑1005 while exploring longer‑term opportunities across its 12‑LOX platform.
The regulatory milestone, combined with the company’s financial constraints, highlights the critical need for additional capital to bring CAD‑1005 to market. Successful completion of the Phase 3 trial could position Cadrenal as a leader in a niche therapeutic area and provide a new revenue stream to address its liquidity needs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.